Biocon Denies API Selloff Rumors As It Completes Biologics Integration
Indian Giant Dismisses Media Reports Of $1.5bn Divestment As ‘Baseless And Speculative’
• By David Wallace
Generate a summary of this article
Listen to this article
Biocon has rejected as “baseless and speculative” Indian media reports that it is considering divestment options for its API business. Meanwhile, the firm has celebrated completion of the integration of Viatris’s biosimilars business into its Biocon Biologics subsidiary.
Biocon has denied reports that it is evaluating options for its API business • Source: Shutterstock
Biocon has dismissed as “baseless and speculative” Indian media reports that the firm was considering options for its active pharmaceutical ingredients business.
A report in India’s Economic Times had suggested that Biocon was evaluating a plan to sell its generic API business...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.